Drug Profile
Research programme: serotonin 3 receptor antagonists - Rottapharm
Alternative Names: CR-3124Latest Information Update: 24 Feb 2010
Price :
$50
*
At a glance
- Originator Rottapharm
- Class
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibromyalgia; Inflammatory bowel diseases; Nausea and vomiting; Substance-related disorders
Most Recent Events
- 05 Dec 2006 CR 3124 is available for licensing (http://www.rotta.com/pages/index.asp)
- 05 Dec 2006 Preclinical trials in Fibromyalgia in Italy (unspecified route)
- 05 Dec 2006 Preclinical trials in Substance-related disorders in Italy (unspecified route)